Edesa Biotech, Inc. Common Shares, also called Edesa Biotech, is a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Read More The company product candidate, EB01 is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. Edesa Biotech was founded on June 12, 2007 and is headquartered in Markham, Canada. The listed name for EDSA is Edesa Biotech, Inc. Common Shares.